The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...
Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...
Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...
GlobalData on MSN1d
Gilead’s Livdelzi shows promise in PBC clinical trialThe analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.
Fintel on MSN3d
Wolfe Research Initiates Coverage of Gilead Sciences (GILD) with Outperform RecommendationFintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...
Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia ...
RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with primary biliary ...
November 15, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback